Wei FF, Zhang J, Jia Z, Yao ZC, Chen CQ. Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report. World J Clin Oncol 2025; 16(3): 101766 [DOI: 10.5306/wjco.v16.i3.101766]
Corresponding Author of This Article
Chun-Qiao Chen, MD, Department of Oncology, People’s Hospital of Guilin, No. 12 Wenming Road, Guilin 541002, Guangxi Zhuang Autonomous Region, China. chencq8302@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Mar 24, 2025; 16(3): 101766 Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101766
Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report
Fei-Fei Wei, Department of Tumor Radiotherapy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region (The Second People’s Hospital of Guangxi Zhuang Autonomous Region), Guilin 541002, Guangxi Zhuang Autonomous Region, China
Jing Zhang, Zhe Jia, Chun-Qiao Chen, Department of Oncology, People’s Hospital of Guilin, Guilin 541002, Guangxi Zhuang Autonomous Region, China
Zhi-Chao Yao, Department of Pathematology, People’s Hospital of Guilin, Guilin 541002, Guangxi Zhuang Autonomous Region, China
Co-first authors: Fei-Fei Wei and Jing Zhang.
Author contributions: Wei FF and Zhang J designed the research, they contributed equally as co-first-authors; Zhang J and Jia Z analyzed the data; Yao ZC and Zhang J performed the research; Wei FF and Chen CQ wrote the paper; and all authors have read and approved the final manuscript.
Supported by Guangxi Guilin Science and Technology Fund, No. 20190218-7-6.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Qiao Chen, MD, Department of Oncology, People’s Hospital of Guilin, No. 12 Wenming Road, Guilin 541002, Guangxi Zhuang Autonomous Region, China. chencq8302@163.com
Received: September 25, 2024 Revised: November 6, 2024 Accepted: December 9, 2024 Published online: March 24, 2025 Processing time: 117 Days and 18.5 Hours
Abstract
BACKGROUND
Most non-small cell lung cancer patients have epidermal growth factor receptor (EGFR) activating mutations, such as exon 19 deletion and exon 21 replacement mutations. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitors approved for the treatment of lung cancer patients carrying EGFR activating mutations. Osimertinib-induced interstitial lung disease (ILD) is a rare and potentially fatal pulmonary toxic manifestation of drug therapy. At present, there is no international consensus on the risks and treatment of the osimertinib-induced ILD.
CASE SUMMARY
We report a case of a 56-year-old woman who was diagnosed with lung adenocarcinoma with lung hilum, mediastinal lymph nodes and brain metastases (T4N3M1c stage IVB). The patient received targeted treatment with osimertinib after radiotherapy and chemotherapy. But she developed ILD after osimertinib treatment. Following active symptomatic treatment and hormone treatment, the lung injury alleviated. The patient was retreated with furmonertinib combined with prednisone and did not experience ILD again. So far, she has survived for 14 months without disease progression.
CONCLUSION
Retreatment with furmonertinib under prednisone could be considered as an effective therapeutic option after risk-benefit assessment for EGFR-mutant lung adenocarcinoma patients.
Core Tip: We report a case of a 56-year-old woman who was diagnosed with lung adenocarcinoma with lung hilum, mediastinal lymph nodes and brain metastases (T4N3M1c stage IVB). The patient received targeted treatment with osimertinib after radiotherapy and chemotherapy, but she developed interstitial lung disease following osimertinib treatment. After active treatment, her lung injury improved. The patient was retreated with furmonertinib combined with prednisone and did not experience interstitial lung disease again. So far, she has survived for 14 months without disease progression. This study suggests that retreatment with furmonertinib under steroid coverage could be considered as an effective therapeutic option after careful risk-benefit assessment for patients with epidermal growth factor receptor-mutant lung adenocarcinoma.
